The Ohio State University Wexner Medical Center
Radiation Oncology residency · Columbus, OH · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is The Ohio State University Wexner Medical Center's research in radiation oncology, which the program shares with other departments and affiliated hospitals.
About The Ohio State University Wexner Medical Centerinstitution-wide radiation oncology research
Radiation Oncology publications from The Ohio State University Wexner Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
284
works per year
19th of 47 radiation oncology residency programs
+18.9%
2-year growth
14th of 47 radiation oncology residency programs
25.1%
in top 10% of field (works before 2025)
13th of 47 radiation oncology residency programs
44.2%
cited above world average
21st of 47 radiation oncology residency programs
Works per year · * 2026 so far
Oncology · 1,287Radiology, Nuclear Medicine and Imaging · 177
Radiation Oncology research topics at The Ohio State University Wexner Medical Center
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 242
- Pancreatic and Hepatic Oncology Research 190
- Cancer survivorship and care 109
- CAR-T cell therapy research 108
- Colorectal Cancer Treatments and Studies 63
- Global Cancer Incidence and Screening 59
- Colorectal Cancer Surgical Treatments 47
- PARP inhibition in cancer therapy 46
Most cited at The Ohio State University Wexner Medical Center since 2024
All radiation oncology papers there on OpenAlex
- Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyAl B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 406
- Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trialSandra P. D’Angelo et al. · The Lancet · 2024 · PubMed · cited 319
- NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024Al B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 312
- Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyJaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network · 2025 · PubMed · cited 243
- CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis et al. · Nature · 2024 · PubMed · cited 201
- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialBradley J. Monk et al. · Annals of Oncology · 2024 · PubMed · cited 197
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine TumorsJennifer Ai-wen Chan et al. · New England Journal of Medicine · 2024 · PubMed · cited 177
- NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024Susan M. Swetter et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 173
- NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024John A. Thompson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 171
- Vaccination of Adults With Cancer: ASCO GuidelineMini Kamboj et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 143